Key terms

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest SNY news

Apr 11 4:46pm ET Meet First Wave BioPharma: Exclusive interview with CEO James Sapirstein Apr 05 5:53am ET Sanofi announces launch of Verorab in UK Apr 04 9:35am ET Barclays Sticks to Its Buy Rating for Sanofi (SNYNF) Apr 03 4:57pm ET Sanofi to resolve roughly 5,000 Zantac lawsuits in U.S., Bloomberg says Mar 27 6:36am ET Dr. Reddy’s enters partnership with Sanofi to distribute vaccines in India Mar 27 6:25am ET AstraZeneca, Sanofi announce Beyfortus approved in Japan Mar 27 6:16am ET Annexon price target raised to $12 from $11 at Wells Fargo Mar 20 2:57pm ET Sanofi’s Amlitelimab Shows Lasting Benefits Mar 19 1:36am ET Sanofi’s Buy Rating Affirmed by Analyst on Strong Clinical Trials and Market Opportunities Mar 13 11:00am ET European Stocks: Unnoticed Records, Overlooked Opportunities Mar 11 6:29am ET Sanofi reports ‘positive’ results from Part 2 of STREAM-AD study Mar 04 8:48am ET Sanofi price target lowered to EUR 114 from EUR 120 at Guggenheim Feb 28 7:39pm ET Inhibrx downgraded to Hold from Buy at Jefferies Feb 25 3:23pm ET Sanofi reports ‘positive’ results from Phase 2 RILECSU study Feb 23 5:16am ET Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA Feb 21 6:19am ET Sanofi’s RSV shot had a bumpy rollout, more popular than expected, WSJ says Feb 20 9:27am ET Sanofi consumer health unit seeing intertest ahead of split, Bloomberg says Feb 20 9:27am ET Sanofi consumer health unit seeing intertest ahead of split, Bloomberg says Feb 20 8:59am ET Denali Therapeutics ALS study failue ‘clearing event,’ says B. Riley Feb 20 8:55am ET Denali continues decline after Sanofi ALS study failure Feb 16 5:26am ET Regeneron, Sanofi announce MHLW in Japan approves Dupixent Feb 15 8:22am ET Sanofi reports Phase 2 data on frexalimab published in NEJM Feb 15 8:09am ET Sanofi announces Phase 2 data published in NEJM on frexalimab Feb 14 4:12pm ET Dianthus initiated with a Buy at Stifel Feb 12 4:42pm ET Sanofi price target raised to EUR 94 from EUR 92 at JPMorgan Feb 07 8:27am ET Sanofi Growth Prospects and Pipeline Potential Affirm Buy Rating Feb 06 8:35am ET Deutsche Bank Sticks to Its Sell Rating for Sanofi (SNYNF) Feb 05 8:52am ET Regeneron price target raised to $1,110 from $1,076 at RBC Capital Feb 05 7:35am ET DZ BANK AG Remains a Hold on Sanofi (SNYNF) Feb 05 6:35am ET UBS Sticks to Their Buy Rating for Sanofi (SNYNF) Feb 05 4:06am ET Buy Rating Affirmed for Sanofi on Strong Sales and Promising Financial Outlook

No recent news articles are available for SNY

No recent press releases are available for SNY

SNY Financials

1-year income & revenue

Key terms

SNY Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

SNY Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms